RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation to our Letters dated April 26, 2024, May 01, 2024 and May 02, 2024, the transcript of the Results Earnings call for the Audited Financial Results for the quarter and year ended March 31, 2024 held on May 02, 2024 at 3.30 p.m. IST is made available on the Company''s website. RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation of loss of share certificate as received by us from Link Intime India Pvt. Ltd.., our Registrar & Share Transfer agent, being submitted to you pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
The Audio recording for the earnings call for Audited FInancial Results of the Company as on March 31, 2024 is attached. Q4FY24 Quarterly & FY24 Annual Result Announced for RPG Life Sciences Ltd.
Pharmaceuticals company RPG Life Sciences announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue Growth: RPG Life Sciences reported a YoY revenue increase for the Q4FY24, with revenue from operations going up from Rs 118.49 crore to Rs 126.99 crore, marking a 7% growth. Profit Before Tax (PBT): The company experienced a significant jump in PBT of 28% YoY for Q4FY24, climbing from Rs 13.81 crore to Rs 17.74 crore. EBITDA Margin Expansion: There has been a notable improvement in EBITDA margins, from 15% to 17.6% YoY for Q4. FY24 Financial Highlights: Revenue Growth: The full-year performance was also strong, with revenues increasing by 14% to Rs 582.05 crore for FY24, up from the previous year's Rs 512.81 crore. Profit Before Tax (PBT): For the full fiscal year, PBT surged by 29%, with figures reaching Rs 117.84 crore compared to the earlier Rs 91.68 crore. EBITDA Margin Expansion: A YoY rise for the full year from 21.0% to 23.3%. Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 7% and 28% respectively YoY. The EBITDA margin retained its 5-yearlong upward trajectory growing from 21.0% to 23.3% YoY. The Company continues to remain debt-free. We are well on course in executing all the tenets of our distinctive and smart transformation agenda to achieve our strategic goal of consistent, healthy, and profitable growth. Our top priority, Domestic Formulations, the biggest contributor to the Company’s business, recorded robust growth in both value and volume - significantly and consistently ahead of the marketbased on its 5 pillar-growth strategy. The comprehensive smart life cycle management program is shaping some of our ‘textbook’ legacy brands into mega brands and our niche specialty portfolio into mega portfolio. New launches in specialty and chronic therapies are helping us shape our Specialty business. We are now working on replicating our smart and successful Rheumatology portfolio entry strategy to enter other specialties like Gastro and Derma to emerge as future growth drivers of Domestic Formulations business. Our MABs portfolio continues to post robust performance. Salesforce productivity continues to register healthy upward momentum, assisted by smart deployment of digital. We are now shaping our International Formulations and API business basis their own 5 pillars, the key being plants modernization cum capacity expansion by infusion of capex and building a smart product pipeline to become strong futuregrowth drivers. The International Formulations business has been registering healthy double-digit growth. Modernization of our API Plant and building product pipeline, both currently underway, will make API also our third engine of growth. Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain 5-year uninterrupted YoY margin expansion trajectory for the past 5 consecutive years.” Result PDF RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith a copy of Investor Presentation with respect to Audited Financial Results of the Company for the quarter and year ended March 31, 2024. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015, please find attached herewith a copy of the newspaper publication with respect to the Audited Financial Results for the quarter and year ended March 31, 2024. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached copy of Press Release with respect to Audited Financial Results of the Company for the quarter and year ended March 31, 2024. RPG LIFE SCIENCES LTD. - 532983 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Details of Related party transactions as on March 31, 2024 are attached. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Change in Directorate
The details of appointment/reappointment of the Directors at the Board Meeting of the Company held on April 30, 2024 are attached.